Captrust Financial Advisors Purchases Shares of 14,041 Hims & Hers Health, Inc. (NYSE:HIMS)

Captrust Financial Advisors acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 14,041 shares of the company’s stock, valued at approximately $340,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SlateStone Wealth LLC grew its position in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in shares of Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares during the period. Harbour Investments Inc. increased its position in shares of Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after purchasing an additional 833 shares during the last quarter. Finally, LPL Financial LLC increased its position in shares of Hims & Hers Health by 1.0% during the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company’s stock valued at $2,369,000 after purchasing an additional 980 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction on Friday, May 16th. The shares were sold at an average price of $58.40, for a total value of $7,482,616.80. Following the transaction, the chief executive officer now directly owns 89,311 shares of the company’s stock, valued at approximately $5,215,762.40. The trade was a 58.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 17,303 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total value of $832,966.42. Following the sale, the insider now owns 193,601 shares of the company’s stock, valued at approximately $9,319,952.14. This represents a 8.20% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 618,936 shares of company stock valued at $25,182,692. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Stock Down 1.8%

Shares of NYSE:HIMS opened at $61.21 on Wednesday. The business’s 50 day moving average is $36.60 and its 200 day moving average is $34.38. The stock has a market cap of $13.70 billion, a P/E ratio of 139.12 and a beta of 1.84. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s revenue for the quarter was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.05 earnings per share. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Citigroup restated a “sell” rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Truist Financial reduced their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. Bank of America lifted their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a research note on Tuesday, April 29th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Finally, UBS Group reissued a “mixed” rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.